Physician profile
Kenneth Lyda
NPI 1043215999
$6,747.48
in general payments reported to CMS, 2019-2025
26 companies · $1,125 in 2025
The $1,125 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $708 · 2022: $924 · 2023: $2,839 · 2024: $1,151 · 2025: $1,125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,944 · Travel and Lodging: $1,171.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,944.36 |
| Travel and Lodging | $1,171.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $1,782.20 | 2022-2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $851.66 | 2021-2025 | Lifevest |
| Abbott Laboratories | $672.38 | 2021-2025 | Aveir, Assurity, Jot Dx |
| Amgen INC. | $543.84 | 2021-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $508.89 | 2021-2024 | Xarelto |
| Boston Scientific Corporation | $453.50 | 2021-2025 | Watchman Flx, Rhythmia Mapping System, Bodyguardian |
| Astrazeneca Pharmaceuticals LP | $432.22 | 2021-2024 | Farxiga, Wainua, Andexxa |
| Edwards Lifesciences Corporation | $286.31 | 2022-2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve, Sapien 3 Ultra Resilia |
| E.R. Squibb & Sons, L.L.C. | $200.65 | 2021-2025 | Eliquis, Camzyos |
| Novartis Pharmaceuticals Corporation | $171.75 | 2023-2025 | |
| Harmony Biosciences LLC | $119.56 | 2022 | |
| Cvrx, INC. | $104.44 | 2021-2025 | Barostim Neo System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $78.72 | 2021-2023 | Jardiance |
| Pfizer INC. | $72.21 | 2021-2023 | |
| Abiomed | $69.62 | 2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $63.34 | 2021-2023 | Uptravi, Opsumit |
| Bayer Healthcare Pharmaceuticals INC. | $59.86 | 2025 | |
| Novo Nordisk INC | $55.85 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $48.33 | 2021-2022 | |
| Chiesi USA, INC. | $40.20 | 2024 | Kengreal |
| Lexicon Pharmaceuticals, INC. | $34.53 | 2023 | Inpefa |
| Eisai INC. | $25.56 | 2024 | |
| Vital Connect, INC | $19.87 | 2023 | Vitalpatch Rtm |
| Heartflow, INC. | $17.86 | 2025 | |
| Merck Sharp & Dohme LLC | $17.80 | 2024 | Verquvo |
| Bridgebio Pharma, INC. | $16.33 | 2025 | Attruby |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Lyda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.